-Update on development of H1N1 pandemic vaccines - M-P. Kieny
-Changing antigenicity of HA and NA: opportunities for improved vaccines - D. Smith
-Role of adjuvants in induction of cross-reactive and long-lasting immune responses - M. Friede
- Conserved and alternative vaccine targets - R. Bright
- Immunological correlates of protection - G. Rimmelzwaan
- Role of CMI in protection against influenza in humans - J. McElhaney
- T cell responses in human influenza virus infection - A. McMichael
- Correlates of efficacy of LAIV - K. Subbarao
- M2 cytoplasmic tail mutants as pandemic vaccine candidates - P. Bilsel
- Influenza B NS-1 truncated mutants as candidate vaccines - J. Romanova
- Protease activation mutants of influenza A and B viruses as candidates for attenuated live vaccines against pandemic and seasonal influenza - J. Stech
- Direct and indirect protection against new variants of influenza A and B with the live attenuated influenza vaccine, 2007-2008 - W.-P. Glezen
- Protection against circulating and drifted variants of influenza virus with the LAIV - I. Kiseleva
- AS03-adjuvanted seasonal vaccines in the elderly - D. Poelaert
- Enhancing the breadth of immunity to influenza VLPs - D. Compans
- Continuous production and purification of a Virus-Like Particle Influenza vaccine from mammalian cell culture - B. Dropulic
-VLPs made in insect cells and presentation of new clinical data - K. Bryett
- Insect cell-produced influenza-pseudotyped virus like particles: Evidence for enhanced immunity and breadth of protection - J. Haynes
- Overview on safety of live-vectored vaccines - R. Le Blanc
- Live-vector approaches including their MVA vector studies - L. Perera
- MVA vector studies in monkeys - A. Osterhaus
Rationale and Design of a Phase 1 Clinical Trial of PaxVax Live, Oral Ad4-Vectored H5N1 Vaccine - K. Kelley
- Non-replicating adenovirus vector as a carrier for the development of rapid-response influenza vaccines - D. Tang
- VLP production in plants - L. Vezina
- Vaccines derived from transient gene expression in tobacco plants - V. Yusibov
- A fungal platform for vaccine production - D. Higgins
- A novel universal influenza vaccine containing M2e and NP with a TLR9 agonist - T. Martin
- Flagellin fused M2e vaccines - A. Shaw - Combined vaccination with split vaccine plus M2e protein - F. Wu
- DNA Vaccines: setback, advances and next steps - J. Beadle
- Improvement of flu vaccine with adjuvants and patch delivery - A. von Gabain
- Nanoemulsion adjuvanted nasal vaccine, a novel means to enhance immunogenicity and broaden cross-protection against influenza - T. Hamouda